The Fed Decides.
These Run on
Company Clocks.
Week of July 27 — ASND · PEN · WATT
A hold is overwhelmingly expected Wednesday — the tone is the event. Meanwhile, this week's three setups are driven by their own catalysts: a biotech crossing into profitability, a medtech pinned by takeover mechanics, and a speculative micro-cap.
A hold is expected — listen to the language
The FOMC meets July 28–29, and the market has largely made up its mind. After June CPI came in well below expectations — headline prices falling 0.4% month-over-month, the annual rate cooling to ~3.5% against a 3.8% consensus — July hike odds collapsed from roughly 40% to about 15%. A hold is the overwhelming expectation.
So the decision isn't the event; the tone is. Chair Warsh has been reluctant to declare victory, and with the U.S.–Iran ceasefire broken and oil rebounding, the energy-driven disinflation that cooled June's print could unwind. Futures still carry meaningful odds of at least one hike before December. Watch the statement language and presser, not the rate line.
This is also the busiest stretch of Q2 reporting. Which is the deliberate idea behind the list: all three names run on company clocks rather than the macro one — a product cycle, a merger agreement, and a deployment ramp.
That independence is the appeal in a week thick with macro noise. It also means the risks here are company risks — and two of these three carry ones we spell out plainly rather than bury.
The standout of the scan
ASND posts the single most extreme statistic we've put in front of you: a 39.48 profit factor — winning periods outweighing losers by nearly forty to one — plus the list's highest annualized return at 105.61%.
Ascendis is a Danish biopharma built on its TransCon drug-delivery platform, spanning endocrinology and rare disease. The critical shift is financial: after years of losses it's crossing into profitability. Consensus looks for ~$1.38 EPS on ~$338.6M revenue this quarter, with full-year estimates swinging from a $4.34 loss to a $0.24 profit.
Ascendis cleaned up its balance sheet by calling all $575M of its 2.25% convertible notes, then monetized an FDA Priority Review Voucher for $187.5M in June — straight non-dilutive cash. Clinical flow has been steady: five-year and 3.5-year TransCon PTH data showing sustained benefit, the completed Phase 3 PaTHway trial, and achondroplasia subgroup data. 26 analysts cover it with an 88% buy consensus, average target ~$305 (Barclays $345, Wells Fargo $326).
Wednesday, August 5, 2026 (after close). Consensus EPS ~$1.38 on revenue ~$338.6M — watch product uptake, the profitability inflection, and pipeline updates.
Largely detached from the Fed — biotech demand doesn't hinge on the funds rate, though a hawkish tone pressures sector risk appetite. The real risks are the ones biotech always carries: binary clinical and regulatory outcomes, real competition in achondroplasia, and a profitability inflection that must be proven quarter by quarter.
A 39.48 profit factor and 105.61% annualized return — the strongest profile on this list — attached to a real story: a biotech crossing into profitability, freshly capitalized by a $187.5M voucher sale, with an 88% buy consensus into an August 5 print. The risks are clinical and competitive, not macro.
High frequency — pinned by a takeover
On raw numbers PEN looks strong — 90% frequency, 81.53% annualized, 80% win rate. But the honest read matters more: PEN's price is no longer set by the market's view of Penumbra.
The underlying business performs. Penumbra is the world's leading thrombectomy company; Q1 revenue rose 15.6% to $374.8M, thrombectomy +12.1%, embolization/access +23.8%, gross margin 67.6%. Clinical flow continues with 90-day STORM-PE results, a European CE Mark for Thunderbolt, and July's FORWARD study launch.
On January 15, Boston Scientific agreed to acquire Penumbra at a headline $374/share (~$14.5B EV), shareholder-approved, closing expected 2H 2026. But consideration is ~73% cash / 27% BSX stock (elect $374 cash or 3.8721 BSX shares, subject to proration) — and BSX has fallen from ~$109.50 last September to roughly $43, down ~58% on guidance cuts and device recalls.
Cash contributes ~$273/share; the stock slice (~1.05 BSX shares of exposure per PEN share) is worth only ~$45. Blended: ~$318 — and PEN trades near $317. The market has priced the deal efficiently, the "$374" headline is stale, and there's no free spread left. That's also why analyst targets cluster at $320–$364, below the headline.
PEN is now a cash floor plus a dampened BSX-recovery stake. About $273 is contractually fixed, cushioning downside; the rest moves with BSX — currently beaten down, with a $5B buyback, directors buying in the mid-$50s, and an average target near $80. Asymmetric, but not a seasonal momentum trade. Deal risks: a break sends PEN toward standalone value (BSX owes $900M on regulatory failure; PEN owes $525M for a superior proposal).
Q2 expected early August 2026 (est.). Penumbra has withheld forward guidance due to the merger — deal-close headlines matter more than the print.
90% frequency, but the price is governed by Boston Scientific's pending $374 takeover — and with BSX down ~58%, the blended consideration sits near $318, right where PEN trades. Treat it as a ~$273 cash floor plus a dampened BSX-recovery stake: asymmetric and macro-insulated, not a directional seasonal trade.
Best frequency — genuine micro-cap speculation
WATT owns two categories outright — the highest frequency at 91.67% and the best annual win rate at 81.82%. But look at the fourth number: a 3.39 profit factor, the lowest here by a wide margin.
That combination is the signature of a high-frequency, high-chop name: the pattern shows up often, but the average win is only modestly larger than the average loss. Position sizing matters more here than anywhere else on this list.
Energous develops over-the-air wireless power — WattUp and PowerBridge deliver RF charging to battery-free devices like retail sensors, shelf labels and asset trackers. Q1 revenue reached ~$3.1M, up 799% year-over-year, a fifth straight quarter of growth, with two active Fortune 10 deployments and a widening pipeline. PowerBridge Pro cleared EU approval in December, and on June 29 the company was added to the Russell 3000 and 2000 — management framed it as a shift from development to production deployments.
Market cap is roughly $22 million. The stock did a 1-for-30 reverse split in August 2025, its 52-week range spans ~$3.62 to $36.98, and it has fallen from ~$33.50 on May 1 to about $15 in mid-July — more than 50% in ten weeks. Coverage is a single analyst. Short-seller Fugazi Research has publicly called it a low-revenue, cash-burning company, and it remains unprofitable (–$0.40 last quarter). Technicals read strongly negative. A genuine speculation, not a core position.
Q2 expected early August 2026 (est.) — trackers differ, some show late July. Verify the date before trading. Watch deployment expansion, revenue trajectory, and cash burn.
No Fed decision drives this business — but micro-caps are among the first casualties when risk appetite tightens, so a hawkish surprise Wednesday would likely hit WATT harder than the other two. Swing factors: deployment news, revenue growth, and the balance sheet.
Best frequency and win rate on the list with real commercial momentum (revenue +799% YoY, two Fortune 10 deployments, fresh Russell inclusion) — but the lowest profit factor signals a choppy ride, and this is a ~$22M micro-cap down 50%+ since May with a short-seller report against it. High-frequency speculation; size it as such.
The three setups, side by side
| Ticker | Frequency | Profit Factor | Ann. Return | Annual Win % | Catalyst |
|---|---|---|---|---|---|
| ASNDAscendis Pharma | 81.82% | 39.48 | 105.61% | 80% | Earnings Aug 5 |
| PENPenumbra | 90% | 4.28 | 81.53% | 80% | BSX takeover pending |
| WATTEnergous | 91.67% | 3.39 | 93.83% | 81.82% | Q2 ~early Aug |
The Big Picture
Three setups, one theme: in a week dominated by the Fed, these run on company clocks — and form a deliberate ladder from quality to speculation.
Read the risk ladder deliberately. If Wednesday's FOMC lands dovish and risk appetite broadens, WATT has the most torque to the upside. If Warsh sounds hawkish and small caps get hit, PEN's contractual cash floor is the ballast and ASND's product cycle keeps running regardless. That spread — quality compounder, structural arbitrage, speculative micro-cap — is how you carry a watchlist through a week when the macro headline is out of your hands.
The goal is never to predict the week perfectly. Seasonality gives you the roadmap; the earnings and deal calendars give you the catalysts; the Fed backdrop tells you which risks to size carefully. From there: watch the price action, respect your stops, and refuse to let emotion decide.
Sign Up to View Full Trade Details →Super Seasonal Trade Desk
